Insmed raises $775M via term loan, royalty deal, and equity offering to fund pipeline

INSMED Inc

$350M senior secured term loan from Pharmakon Advisors, maturing Oct 2027, at SOFR+7.75% (floor 2.5%).
$150M synthetic royalty deal with OrbiMed: 4-4.5% of ARIKAYCE sales + 0.75% of brensocatib sales, capped at 1.8-1.9x.
$275M equity offering: 13.75M shares at $20.00; closing expected Oct 21, 2022.
Pro forma cash and marketable securities ~$1.3B; proceeds to fund ARIKAYCE commercial launch, brensocatib readiness, and R&D.
Term loan and royalty financing closed Oct 19, 2022; equity underwriting with J.P. Morgan and SVB Securities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.